Acumen research and consulting estimates that the global sleep apnea diagnostics market is anticipated to reach market size of around US$ 170 Mn by 2027 and is anticipated to grow at a CAGR of around 7% in terms of revenue during the forecast period 2020 – 2027. Sleep apnea is a sleep disorder which fluctuates with the breathing pattern of the patient. The patient's breathing during sleep will decrease or even stop completely. The breath (called apnea) in some cases it can be paused, lasting 10 seconds or more, and can occur 30 times or more in one hour. Daytime dreaming, heavy snoring and disturbed sleep are the symptoms of sleep apnea. About 18 million Americans are suffering from sleep apnea, while 20% are diagnosed and treated.

Market Insights

Increasing geriatric population and rise in sedentary lifestyle diseases include diabetes & other are the major factors that flourish the growth of global sleep apnea diagnostics market and is projected to grow during forecast period. The risk factor for the development and progression of sleep apnea is considered to be obesity. Additionally, technological improvements that make products more comfortable for patients and significant increase in sleep apnea disorders fuel global market growth. However, such procedures are likely to sustain high prices, limitations on the reimbursement of such products, and a low patient awareness of sleep apnea. In fact, the rise in patient preference for home healthcare services is anticipated in the near future to generate lucrative growth opportunities.

Report coverage

The market research study on “Sleep Apnea Diagnostics Market (By Product: Polysomnography Device (PSG), Clinical PSG Device, Ambulatory PSG Device, Sleep Apnea Screening Device, Actigraphy Monitoring Device, Respiratory Polygraph Oximeter, Finger Tip Oximeter, Handheld Oximeter, Wrist-worn Oximeter, Tabletop Oximeter, Others; By End-User: Hospitals & Sleep Laboratories, Home Care Settings) - Global Industry, Analysis, Market Size, Opportunities and Forecast, 2020 - 2027” offers detailed insights on the global sleep apnea diagnostics market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report also provides competitive landscape to understand the current stance of particular player. The report provides insights on global sleep apnea diagnostics market are product, end-user, and major geographic regions. The sleep apnea diagnostics market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report.

North America accounts to hold large market share of global sleep apnea diagnostics market due to increasing awareness regarding the disease, professional sleep therapists and doctors and rise in reimbursement policies. The primary causes of obstructive medical sleep apnea are also the main drivers of the key players to launch products to the North American market. Due to the availability of qualified health care professionals and supporting government policies in the field of health services are the factors that are expected to grow the Europe market and country such as Germany, France and the UK is likely to follow the direction of North America. In the obstructive sleep-apnea treatment segment, Asia Pacific is expected to report an significant CAGR because of the high prevalence of this condition. The higher AGRs in the world are anticipated during the forecast period in Asia-Pacifical countries , such as China, Japan and India. Latin American and Middle East and Africa were less aware of the disorder and associated care services and received a lower sleep apnea-diagnostic market share.

Key Players

Major players included in this report are DeVilbiss Healthcare LLC., Cadwell Laboratories Inc., Medtronic plc, Koninklijke Philips N.V., Mindray, Natus Medical Incorporated, Resmed, Nihon Kohden Corporation, Smiths Medical, SomnoMedics, Becton, Dickinson and Company, BMC Medical Co., Ltd., Fisher & Paykel Healthcare, and others. In 2019, all the dominant players, including ResMed, Koninklijke Philips, Fisher & Paykel Healthcare, New Zealand, accounted for approximately 94.4% of the worldwide sleep apnea treatment markets and, due to their significant product advancement and growth of regional marketing approaches, the remaining players accounted for approximately 5.6% of the industry combined.

The global sleep apnea diagnostics market is segmented as below:

Market Segmentation

Sleep Apnea Diagnostics Market By Product

Polysomnography Device (PSG)

• Clinical PSG Device
• Ambulatory PSG Device

Sleep Apnea Screening Device

Actigraphy Monitoring Device

Respiratory Polygraph

Oximeter

Finger Tip Oximeter

• Handheld Oximeter
• Wrist-worn Oximeter
• Tabletop Oximeter

Others

Sleep Apnea Diagnostics Market By End-User

Hospitals & Sleep Laboratories

Home Care Settings

Sleep Apnea Diagnostics Market By Geography

North America

• U.S
• Canada

Europe

• UK
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENT